S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
$13.17
+0.4%
$11.51
$6.64
$35.52
$12.87M1.87479,845 shs17,400 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.56
-5.1%
$0.46
$0.37
$1.62
$2.72M0.45388,602 shs781,634 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$1.71
-2.8%
$1.87
$0.97
$5.10
$7.32M0.5929,818 shs6,766 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
0.00%0.00%0.00%0.00%0.00%
Dynatronics Co. stock logo
DYNT
Dynatronics
-4.91%+39.08%+28.48%+3.11%-62.41%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-3.12%-8.56%-7.57%-20.47%-60.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
1.8479 of 5 stars
3.05.00.00.02.50.00.6
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.7068 of 5 stars
3.53.00.00.00.00.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
2.00
Hold$3.80583.08% Upside
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.00
Buy$10.00484.80% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/A$4.77 per shareN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
$40.61M0.07N/AN/A$2.19 per share0.25
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$4.91M1.49N/AN/A($0.30) per share-5.70

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
-$5.62MN/A0.00N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
-$4.97M-$1.38N/AN/A-14.13%-54.88%-16.14%5/9/2024 (Estimated)
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$13.32M-$33.76N/AN/AN/A-271.04%-805.57%-97.73%N/A

Latest DYNT, PSTV, and APOP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/5/2024Q4 2023
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.78-$0.70+$0.08-$0.70$1.26 million$1.31 million
2/7/2024Q2 2024
Dynatronics Co. stock logo
DYNT
Dynatronics
N/A-$0.27-$0.27-$0.27N/A$8.15 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
3.01
3.01
Dynatronics Co. stock logo
DYNT
Dynatronics
0.21
1.41
0.67
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
0.92
0.92

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
4.84%
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%

Insider Ownership

CompanyInsider Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
Dynatronics Co. stock logo
DYNT
Dynatronics
9.10%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.32%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
2,020977,000N/ANot Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
1544.88 million4.44 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
204.28 million4.18 millionNot Optionable

DYNT, PSTV, and APOP Headlines

SourceHeadline
Plus Therapeutics, Inc. (PSTV)Plus Therapeutics, Inc. (PSTV)
finance.yahoo.com - April 19 at 12:11 AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
finance.yahoo.com - April 9 at 7:57 AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.
globenewswire.com - April 9 at 7:00 AM
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferencePlus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
finance.yahoo.com - March 27 at 10:29 AM
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell DiagnosticPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
finance.yahoo.com - March 25 at 8:51 AM
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry TailwindsBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
markets.businessinsider.com - March 23 at 7:41 AM
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal MetastasesPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
finance.yahoo.com - March 11 at 9:16 AM
Plus Therapeutics Full Year 2023 Earnings: Beats ExpectationsPlus Therapeutics Full Year 2023 Earnings: Beats Expectations
finance.yahoo.com - March 7 at 10:46 AM
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call TranscriptPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 7 at 10:46 AM
Q4 2023 Plus Therapeutics Inc Earnings CallQ4 2023 Plus Therapeutics Inc Earnings Call
finance.yahoo.com - March 6 at 6:24 PM
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
investorplace.com - March 5 at 10:33 PM
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue EstimatesPlus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
zacks.com - March 5 at 6:36 PM
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
globenewswire.com - March 5 at 4:05 PM
IMUNON stock rallies 19% on early results for COVID-19 vaccineIMUNON stock rallies 19% on early results for COVID-19 vaccine
msn.com - February 29 at 1:33 PM
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
finance.yahoo.com - February 27 at 8:49 AM
Plus Therapeutics Inc PSTVPlus Therapeutics Inc PSTV
morningstar.com - February 21 at 6:55 PM
Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0
knoxdaily.com - January 1 at 10:51 PM
Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024
finanznachrichten.de - December 18 at 1:46 PM
Plus Updates Financial and Cash Guidance for 2024Plus Updates Financial and Cash Guidance for 2024
finance.yahoo.com - December 18 at 8:46 AM
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker AnalysesPlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
finance.yahoo.com - December 12 at 10:20 AM
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)
markets.businessinsider.com - November 29 at 8:56 AM
Fortress Biotech, Plus Therapeutics among healthcare moversFortress Biotech, Plus Therapeutics among healthcare movers
msn.com - November 20 at 2:51 PM
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader WebinarPlus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
finance.yahoo.com - November 20 at 9:51 AM
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
finance.yahoo.com - November 15 at 10:12 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cellect Biotechnology logo

Cellect Biotechnology

NASDAQ:APOP
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Dynatronics logo

Dynatronics

NASDAQ:DYNT
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.
Plus Therapeutics logo

Plus Therapeutics

NASDAQ:PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.